These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26598279)

  • 1. The efficacy, bioavailability and safety of a novel hydroalcoholic testosterone gel 2% in hypogonadal men: results from phase II open-label studies.
    Efros M; Carrara D; Neijber A
    Andrologia; 2016 Aug; 48(6):637-45. PubMed ID: 26598279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
    Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
    J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of testosterone replacement gel for treating hypogonadism in men: Phase III open-label studies.
    Belkoff L; Brock G; Carrara D; Neijber A; Ando M; Mitchel J
    Andrologia; 2018 Feb; 50(1):. PubMed ID: 28295450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study.
    Meikle AW; Arver S; Dobs AS; Sanders SW; Rajaram L; Mazer NA
    J Clin Endocrinol Metab; 1996 May; 81(5):1832-40. PubMed ID: 8626843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and relative bioavailability of absorbed testosterone after administration of a 1.62% testosterone gel to different application sites in men with hypogonadism.
    Miller J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Endocr Pract; 2011; 17(4):574-83. PubMed ID: 21454244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
    Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B;
    J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of skin washing on systemic absorption of testosterone in hypogonadal males after administration of 1.62% testosterone gel.
    Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Curr Med Res Opin; 2012 Feb; 28(2):271-9. PubMed ID: 22185431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men.
    Meikle AW; Matthias D; Hoffman AR
    BJU Int; 2004 Apr; 93(6):789-95. PubMed ID: 15049991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM.
    Cunningham G; Belkoff L; Brock G; Efros M; Gittelman M; Carrara D; Neijber A; Ando M; Mitchel J
    Endocr Pract; 2017 May; 23(5):557-565. PubMed ID: 28225313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index.
    Dobs A; Norwood P; Potts S; Gould E; Chitra S
    J Sex Med; 2014 Mar; 11(3):857-64. PubMed ID: 24283410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natesto™ , a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men.
    Rogol AD; Tkachenko N; Bryson N
    Andrology; 2016 Jan; 4(1):46-54. PubMed ID: 26695758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel testosterone 2% gel for the treatment of hypogonadal males.
    Dobs AS; McGettigan J; Norwood P; Howell J; Waldie E; Chen Y
    J Androl; 2012; 33(4):601-7. PubMed ID: 21979302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study.
    Kaufman JM; Miller MG; Fitzpatrick S; McWhirter C; Brennan JJ
    J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men.
    Kaufman JM; Miller MG; Garwin JL; Fitzpatrick S; McWhirter C; Brennan JJ
    J Sex Med; 2011 Jul; 8(7):2079-89. PubMed ID: 21492400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men.
    Raynaud JP; Legros JJ; Rollet J; Augès M; Bunouf P; Sournac M; Fiet J
    J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):168-76. PubMed ID: 18325757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial.
    Kühnert B; Byrne M; Simoni M; Köpcke W; Gerss J; Lemmnitz G; Nieschlag E
    Eur J Endocrinol; 2005 Aug; 153(2):317-26. PubMed ID: 16061839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men--a clinical research center study.
    Wang C; Iranmanesh A; Berman N; McDonald V; Steiner B; Ziel F; Faulkner SM; Dudley RE; Veldhuis JD; Swerdloff RS
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2749-57. PubMed ID: 9709942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency.
    McMahon CG; Shusterman N; Cohen B
    J Sex Med; 2017 Jul; 14(7):883-890. PubMed ID: 28673432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.